This week, Rhythm Pharmaceuticals, a biopharmaceutical company specializing in the treatment of rare genetic diseases surrounding obesity, announced the U.S. […]
On October 28, Science Magazine took a look at the arguably sordid regulatory history of Gilead Sciences’ remdesivir. On October 8, Gilead […]
Gilead Sciences, Inc. (Nasdaq: GILD) recently announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug […]
The U.S. Food and Drug Administration approved Aimmune Therapeutics’ Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may […]
Dayvigo (lemborexant), developed and sponsored by Eisai, was approved by the Food and Drug Administration (FDA) for the treatment of […]
2019 was a promising year for cystic fibrosis (CF) patients as a new drug called Trikafta was approved by the […]
Gustave Roussy Institute and Paris-Sud researchers and engineers have developed an artificial intelligence system called Resolved2. The program has been […]
Unique directions for taking first oral GLP-1 may cause a compliance issue; it’s not as simple as just taking a […]
Biogen and its Japanese partner Eisai announced Oct. 22nd an unexpected reversal—pharmaceutical giant Biogen said it will pursue US Food […]
The U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, major morbidity of systemic […]
